A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas.

ABSTRACT:

Background

Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma.

Objective

This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies.

Methods

The researchers conducted a systematic literature review for each research question on scientific databases and surveyed a panel of experts for each therapeutic procedure's specific drivers that contributed to its total cost.

SUBMITTER: Basile M 

PROVIDER: S-EPMC10788683 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature